Metabolism Disorder TRIZ Cases

Plasminogen converts to plasmin to dissolve microthrombi and repair vascular injuries in diabetic patients.

An implantable microneedle patch releases glucagon through insulin aptamer conjugates to prevent hypoglycemia without lagging feedback.

Linking branched polyethylene glycol to exendin-4 extends blood half-life while reducing immunogenicity and preserving GLP-1 receptor binding affinity.

Temperature programming and cryopreservation stimulate modified stem cells to secrete G-CSF, Fractalkine, EGF, IL-4, IL-5, and IL-13 simultaneously.

Antibody peptide conjugates resist DPP-IV cleavage to extend half-life while activating dual receptors for safer glycemic control.

A GLP-1 receptor agonist conjugated to vitamin B12 complexes with intrinsic factor for subcutaneous delivery.

Tri-valent sugar cluster insulin conjugates bind endogenous carbohydrate-binding proteins to deliver glucose-responsive insulin without immunogenic lectins.

Lysine, arginine, and HMB combination protects beta cells from deterioration while improving glucose control.

A self-cleaving linker conjugates insulin to a PEG hydrogel prodrug for sustained release.

Combining rapid-acting insulin analog with pramlintide suppresses glucagon to resolve postprandial hyperglycemia control issues.

One-pot reaction conjugates insulin-ester with activated oligomer to produce stable insulin-oligomer conjugates.

PTH1R antibodies function as negative modulators that block PTH binding, reducing hypercalcemia symptoms without increasing treatment complexity.

Suppressing NGN3 expression enriches non-endocrine progenitors to accelerate in vivo maturation and resolve long cell development times.

Lysine-modified GLP-1 analogs resist enzymatic degradation to extend plasma half-life for metabolic disease treatment.

Sulfonate-based glucagon antagonists resolve the trade-off between high receptor binding affinity and oral bioavailability through structural parameter changes.

Oral Campomanesia pubescens essential oil absorbs plasma glucose, replacing insulin injections to eliminate injection discomfort and reduce treatment costs.

Sequential growth factor treatment guides pluripotent stem cells through definitive endoderm stages to produce functional pancreatic hormone-secreting cells.

A multimodal drug delivery system segments nordihydroguaiaretic acid into stomach and intestinal release portions to optimize absorption kinetics.

D-amino acid substitutions in GIP hybrids prevent DPP-IV degradation, extending glucose-lowering duration while avoiding gastrointestinal side effects.

Urinary phenylacetylglutamine excretion tracks nitrogen scavenging drug dosage adjustments.

Combines prandial insulin with amylin receptor agonist to support body weight control in patients.

Cardiotrophin-1 resolves leptin resistance and adverse effects by modulating glucose transport.

Amorphous metal phosphate salt carrier encapsulates bitter polyphenols, masking taste while protecting against oxidation through pH-triggered release.

A pharmaceutical formulation of insulin aspart uses sorbitol and zinc to maintain chemical stability in aqueous solution.

A four-step chemically defined protocol differentiates pluripotent cells into pancreatic progenitors using specific growth factors and signaling inhibitors.

Oral HDAC6 inhibitors treat metabolic disease and HFpEF by reducing cardiac fibrosis and improving mitochondrial function.

DPP IV inhibitors prevent incretin degradation to lower HbA1c values and reduce diabetic complication risks in at-risk patient groups.

Azelaic acid activates the Olfr544 receptor to promote triglyceride hydrolysis in adipose tissue, avoiding severe side effects of traditional obesity drugs.

N-methylbarbituric acid reacts with a halogenating reagent to form an intermediate compound for alogliptin synthesis.

Herbal formula reduces cholesterol and triglyceride levels via enzyme inhibition, avoiding statin-induced diabetes risk.

A pharmaceutical composition comprising an acylated insulin derivative, glycerol, phenol, m-cresol, and zinc ions to promote stable hexamer formation.

Surrogate pancreatic cells differentiate from non-pluripotent progenitors using defined reagents, resolving impurity and tumorigenic risks in diabetes therapy.

A colon-targeted glutamine formulation bypasses the upper digestive tract to stimulate endogenous gut hormone release.

Ion exchange resins and cyclodextrin polymers remove fibrils and preservatives from insulin, extending infusion set lifespan by preventing inflammation.

A monovalent antibody targets human tumor necrosis factor receptor 1 to treat nonalcoholic steatohepatitis.

Low molecular weight polymeric conjugates achieve glucose-proportional insulin release while resisting enzymatic degradation.

GABAA receptor agonists modulate insulin granule exocytosis to reduce beta cell stress while maintaining glucose control.

Composite GIP receptor agonist polypeptides restore insulin secretion and bone reconstruction by mediating cAMP/PKA signaling in osteoblasts.

Hydrogen peroxide scavenging by copolymers triggers nanoparticle disassembly and insulin release to maintain normoglycemia without hypoglycemia.

An APL peptide induces apoptosis in activated T cells to neutralize pathogenic clones.

Branched acylation via tri-radical linkers extends GLP-1 half-life for monthly dosing.

Patsnap Eureka examines purified microbial compositions altering gut microbiota to reduce fasting blood glucose and inflammation in metabolic syndrome.

Neuregulin-1 activates PI3K/Akt pathways to protect cardiomyocytes from diabetic damage, reducing mortality in heart failure patients.

PEGylated insulin lispro extends duration of action while reducing intra-injection variability through optimized polyethylene glycol conjugation.

Targeted mutations at the FW2/CDR2 junction tune binding specificity, resolving trade-offs between extended circulation and receptor cross-linking risks.

Saccharomyces boulardii yeast cells resolve the contradiction between in vitro extraction capability and in vivo efficacy by lowering cholesterol levels.

Converting free BCAAs into alanyl-leucine dipeptides eliminates bitter taste while maintaining nitrogen balance and physiological effectiveness.

A 64Zn-enriched zinc composition enhances insulin sensitivity and glucose metabolism.